While some studies have indicated negative associations of prognosis with key driver alterations in NRAS, BRAF, and KIT in melanoma patients [2, 6–8], contradictory claim about the role of BRAF mutation in predicting outcomes in Korean patients with primary acral lentiginous melanoma (ALM) has also been made [9]. The gene discussed is KIT; the disease is acral lentiginous melanoma.